AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Nicox Extends Equity Financing with Vester Finance, Adds 5 Million Shares
ByAinvest
Friday, Aug 8, 2025 1:32 am ET1min read
Nicox has extended its flexible equity financing with Vester Finance by adding 5 million shares, which is a maximum of 6.43% of the currently issued share capital. The confirmation of Phase 3 results for NCX 470 Denali is expected in mid-August to mid-September 2025. The company estimates it is financed into Q3 2026 and the financing could be extended depending on performance.
Nicox SA, a leading international ophthalmology company, has recently announced the extension of its flexible equity financing agreement with Vester Finance. The company has added 5 million shares, representing a maximum of 6.43% of the currently issued share capital. This move underscores Nicox's commitment to securing financial stability and supporting its ongoing clinical trials, particularly for its lead product candidate, NCX 470.The Phase 3 clinical trial results for NCX 470 Denali, which are expected between mid-August and mid-September 2025, are a critical milestone for Nicox. The company anticipates being financed into Q3 2026, with the potential for further extensions based on performance.
In parallel, Nicox's exclusive Japanese partner, Kowa, has initiated a Phase 3 safety clinical trial of NCX 470 for the treatment of ocular hypertension in Japan. This trial, which triggered a €2 million milestone payment to Nicox, is part of the broader effort to secure marketing approval for NCX 470 in Japan [1][2]. Kowa is responsible for financing and managing the trials under the February 2024 license agreement with Nicox.
Nicox's flexible equity financing and the progress of its clinical trials highlight the company's strategic approach to securing regulatory approvals and commercializing its innovative ophthalmology solutions. The company continues to generate revenue from its products, including ZERVIATE® in allergic conjunctivitis, and its first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb.
References:
[1] https://www.globenewswire.com/news-release/2025/08/05/3127028/0/fr/Nicox-annonce-l-initiation-par-son-partenaire-Kowa-d-un-essai-clinique-de-Phase-3-pour-NCX-470-au-Japon.html
[2] https://www.morningstar.com/news/globe-newswire/1001121338/nicoxs-partner-kowa-initiates-ncx-470-phase-3-clinical-trial-in-japan
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet